Tarsus Pharmaceuticals is a commercial stage biopharmaceutical company focused on eye care therapeutics. It launched XDEMVY (lotilaner ophthalmic solution) 0.25% in August 2023, the first and only FDA-approved treatment for Demodex blepharitis, generating over $646 million in net product sales launch-to-date. The company's pipeline includes TP-04, an investigational gel formulation of lotilaner for ocular rosacea, and TP-05, an investigational oral tablet for Lyme disease prophylaxis and community malaria reduction. Tarsus has completed seven clinical trials for XDEMVY and is advancing lotilaner-based products across eye care and infectious disease prevention.
expected 2026-11-05
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-23 | 2025-12-31 | 0001819790-26-000019 | EDGAR | 107K words |
| 2025-02-25 | 2024-12-31 | 0001819790-25-000011 | EDGAR | 109K words |
| 2024-02-27 | 2023-12-31 | 0001819790-24-000018 | EDGAR | 104K words |
| 2023-03-17 | 2022-12-31 | 0001819790-23-000007 | EDGAR | 98K words |
| 2022-03-14 | 2021-12-31 | 0001819790-22-000010 | EDGAR | 97K words |
| 2021-03-31 | 2020-12-31 | 0001819790-21-000010 | EDGAR | 101K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-11-03 | 2026-09-30 | 0001819790-26-000076 | EDGAR | 85K words |
| 2026-08-06 | 2026-06-30 | 0001819790-26-000064 | EDGAR | 79K words |
| 2025-11-04 | 2025-09-30 | 0001819790-25-000121 | EDGAR | 75K words |
| 2025-08-06 | 2025-06-30 | 0001819790-25-000108 | EDGAR | 75K words |
| 2025-05-01 | 2025-03-31 | 0001819790-25-000078 | EDGAR | 73K words |
| 2024-11-13 | 2024-09-30 | 0001819790-24-000129 | EDGAR | 77K words |
| 2024-08-08 | 2024-06-30 | 0001819790-24-000111 | EDGAR | 76K words |
| 2024-05-08 | 2024-03-31 | 0001819790-24-000063 | EDGAR | 74K words |
| 2023-11-09 | 2023-09-30 | 0001819790-23-000080 | EDGAR | 31K words |
| 2023-08-10 | 2023-06-30 | 0001819790-23-000071 | EDGAR | 29K words |
| 2023-05-09 | 2023-03-31 | 0001819790-23-000030 | EDGAR | 25K words |
| 2022-11-09 | 2022-09-30 | 0001819790-22-000042 | EDGAR | 25K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-11-03 | 0001819790-26-000074 | EDGAR | 4K words |
| 2026-09-10 | 0001819790-26-000066 | EDGAR | 1K words |
| 2026-08-06 | 0001819790-26-000063 | EDGAR | 4K words |
| 2026-08-06 | 0001819790-26-000062 | EDGAR | 22K words |
| 2026-08-06 | 0001819790-26-000060 | EDGAR | 2K words |
| 2026-07-13 | 0001819790-26-000048 | EDGAR | 0K words |
| 2026-02-23 | 0001819790-26-000017 | EDGAR | 4K words |
| 2026-02-18 | 0001819790-26-000005 | EDGAR | 1K words |
| 2026-01-12 | 0001819790-26-000002 | EDGAR | 1K words |
| 2025-11-04 | 0001819790-25-000120 | EDGAR | 4K words |
110 total filings indexed. 82 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001819790 |
| Ticker | TARS |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.tarsusrx.com |
| Listed | 2020-10-16 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/TARS (~200 tokens, structured JSON with cryptographic provenance)